Negative Growth Effects of Ciglitazone on Kidney Interstitial Fibroblasts: Role of PPAR-γ
- 24 April 2003
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 26 (1) , 2-9
- https://doi.org/10.1159/000069764
Abstract
Background/Aims: Ciglitazone and other thiazolidinedione compounds are peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands and improve renal function in diabetic nephropathy independent of blood glucose control. Because interstitial fibroblasts and glomerular mesangial cells are important cell types affected in diabetic nephropathy, the major aim of the present study was to examine the effect of ciglitazone on apoptosis and growth of renal interstitial fibroblasts (NRKs) and glomerular mesangial cells (MMCs). Methods: The effect of ciglitazone on apoptosis and cell growth of cultured NRKs and MMCs was done using DNA fragmentation and MTS cell-growth assays, respectively. The potential role of PPAR-γ in these two cell types was examined by reporter gene analysis. Results: Ciglitazone induced caspase-dependent apoptosis of both NRKs and MMCs and caused a significant decrease in cell growth. Other PPAR-γ ligands also mimicked this effect. Interestingly, ciglitazone did not activate the PPRE-TK-CAT (peroxisome proliferator regulatory element, a thymidine kinase promoter and a chloramphenicol acetyltransferase gene) when transfected into NRKs, suggesting that ciglitazone does not activate the endogenous PPAR-γ system in NRKs. On the other hand, ciglitazone activated the endogenous PPAR-γ in MMCs. Conclusions: Apoptotic and negative growth effects of ciglitazone, in NRKs, are not mediated through PPAR-γ. The thiazolidinediones have important cellular effects on renal interstitial fibroblasts and glomerular mesangial cells that may be therapeutically useful in non-diabetic renal disease.Keywords
This publication has 15 references indexed in Scilit:
- 15-Deoxy-Δ12,14-prostaglandin J2 regulates mesangial cell proliferation and deathKidney International, 2002
- Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal diseaseKidney International, 2001
- Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2Kidney International, 2001
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001
- New Oral Therapies for Type 2 Diabetes Mellitus: The Glitazones or Insulin SensitizersAnnual Review of Medicine, 2001
- Peroxisome Proliferator-activated Receptor δ (PPARδ)-mediated Regulation of Preadipocyte Proliferation and Gene Expression Is Dependent on cAMP SignalingJournal of Biological Chemistry, 2001
- PPAR δ agonists stimulate oligodendrocyte differentiation in tissue cultureGlia, 2001
- Insulin Resistance and Its Treatment by ThiazolidinedionesRecent Progress in Hormone Research, 2001
- Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ)Molecular and Cellular Biology, 2000
- Peroxisome Proliferator-activated Receptor α Inhibits Hepatic S14 Gene TranscriptionPublished by Elsevier ,1996